Regulatory Testing for LUCID-TTM: A Dual Therapeutic Device for Non-Invasive Mitochondrial Modulation and Targeted Temperature Management in TBI Patients
Novel device combining near infrared light therapy and targeted temperature management to maximize neuroprotection in TBI patients.
Project at a Glance
Product Type:
Therapeutic Device
Project Start Date:
7/1/2019
Principal Investigators: Thomas H. Sanderson, PhD
Joseph M. Wider, PhD
Samuel Tuck, MSE
Solution Sheet:
Download Solution Sheet (PDF)
Funding History:
$491,211 in non-dilutive funding • 2019 $128,044 Massey Grand Challenge • 2019 $40,000 Schwabauer Accelerator Award • 2021 $168,948 Massey Grand Challenge
• 2022 $154,219 Massey Grand Challenge
• Substantial departmental, school and center based support
Overview
The project team is developing a single treatment device that combines novel near infrared light (NIR) technology developed in the Sanderson and Hüttemann labs with targeted temperature management (TTM) to target the cellular injury processes occurring during the secondary phase and limit the progression of brain damage.
The team’s preliminary data supports the neuroprotective effects of NIR following ischemia or trauma. Additionally, preclinical and clinical studies have demonstrated the neuroprotective efficacy of prevention of hyperthermia following acute neurologic injurywith targeted temperature management.
Significant Need
Traumatic brain injury is a complex and heterogeneous injury, with injury progression divided into multiple phases.
The primary injury of TBI is caused by mechanical stress applied to the tissue and causes irreversible damage.
In contrast, secondary injury progresses over the ensuing hours, providing an opportunity to rescue damaged tissue and limit brain injury.
Competitive Advantage
The device will provide NIR therapy deep into the brain with simultaneous active surface cooling with feedback temperature sensing to provide TTM.
The team’s goal is to develop and test their newly invented Light Utilizing COX-Inhibitory Device with Targeted Temperature Management (LUCID-TTM), to produce a clinical device for dual NIR and TTM therapy to maximize neuroprotection in TBI patients.
Funding Organization(s)
Publications
None at this time